NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

RecruitingN/A

Sponsor: Regeneron Pharmaceuticals

Conditions: Adverse Pregnancy Outcomes, Atopic Dermatitis

Interventions: dupilumab

Countries: United States

The objective of this study is to describe and compare the incidence of adverse pregnancy outcomes (spontaneous abortion/miscarriage, stillbirth) and prevalence of adverse infant outcomes (major congenital malformations \[MCMs\], small for gestational age \[SGA\]) in women with AD who are treated with dupilumab during pregnancy relative to women with AD who are not treated with dupilumab during pregnancy.

Eligibility overview

Sex: FEMALE

Age: 18 Years to 49 Years

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Key Inclusion Criteria:

* Continuous medical and pharmacy benefit coverage for at minimum 6 months prior to and including the estimated LMP
* Diagnosis code indicative of AD in the period from up to 1 year prior to the estimated LMP through the end of the pregnancy

Note: Other Protocol Defined Inclusion / Exclusion Criteria Apply

Locations (1)

Boston, Massachusetts, United States